期刊
KIDNEY INTERNATIONAL
卷 90, 期 6, 页码 1175-1183出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2016.09.010
关键词
antidiabetic agents; cardiovascular disease; chronic kidney disease; diabetes; glycemic control; renoprotection
资金
- Abbvie
- Astellas
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Eli Lilly
- GlaxoSmithKline
- Janssen
- Novo Nordisk
- Pharmalink
- Relypsa
- Servier
- Pfizer
- Celgene
- Daiichi Sankyo
- Takeda
- National Heart, Lung, and Blood Institute
- Veterans Administration
- Akebia
- Amgen
- Bristol Myers Squibb
- Otsuka
- UCB Celltech
- Vifor
- British Heart Foundation
- Healthcare Quality Improvement Partnership
- Kidney Research UK
- National Institute for Health Research
- Australian National Health & Medical Research Council
- KDIGO
- Bayer HealthCare
- Fresenius Medical Care
- Merck
- Roche
- ZS Pharma
- Alberta Innovates [201300672] Funding Source: researchfish
The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据